Sugi Predict

Sugi Predict / Compounds / SCHEMBL971425

SCHEMBL971425

SCHEMBL971425

c1ccc(COC[C@H]2CNCCO2)cc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SLC6A2 P23975 8/20 0.55
▸ SLC6A4 P31645 7/20 0.55
▸ SLC6A3 Q01959 6/20 0.55
▸ HTR2A P28223 4/20 0.55
▸ HTR2B P41595 2/20 0.55
▸ ADRB2 P07550 1/20 0.55
▸ HTR1A P08908 1/20 0.55
▸ ADRA1A P35348 1/20 0.55
▸ ADRA2C P18825 1/20 0.55
▸ LMNA P02545 1/20 0.54
▸ HRH1 P35367 1/20 0.45
▸ OPRD1 P41143 1/20 0.45
▸ OPRK1 P41145 1/20 0.45
▸ HTR3A P46098 1/20 0.45
▸ BCHE P06276 1/20 0.43
▸ ACHE P22303 1/20 0.43
▸ HRH4 Q9H3N8 4/20 0.42
▸ HRH3 Q9Y5N1 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3031655 1.00 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3HTR2AHTR2B
SCHEMBL971427 1.00 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3HTR2AHTR2B
Maleic Acid SCHEMBL10843397 0.90 LMNA (0.48) SLC6A2SLC6A4SLC6A3HTR2AHTR2B
Fumaric Acid SCHEMBL10843401 0.90 LMNA (0.48) SLC6A2SLC6A4SLC6A3HTR2AHTR2B
SCHEMBL17749334 0.87 LMNA (0.49) SLC6A2SLC6A4SLC6A3HTR2AHTR2B
SCHEMBL28303546 0.87 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3HTR2AHTR2B
SCHEMBL26668485 0.86 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3HTR2AHTR2B
SCHEMBL31381398 0.86 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3HTR2AHTR2B
SCHEMBL26668478 0.86 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3HTR2AHTR2B
Oxalic Acid SCHEMBL10846796 0.86 HTR2B (0.46) SLC6A2SLC6A4SLC6A3HTR2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007117482-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 — — WO claimed
US-20230053411-A1 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES BAYER AKTIENGESELLSCHAFT (DE) 2023-02-23 — — US disclosed
US-20230053411-A1 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES BAYER AKTIENGESELLSCHAFT (DE) 2023-02-23 — — US disclosed
CN-110256418-B 1, 3-thiazol-2-yl substituted benzamides 拜耳公司 2023-01-20 — — CN disclosed
US-11142523-B2 1,3-thiazol-2-yl substituted benzamides BAYER AKTIENGESELLSCHAFT (DE) 2021-10-12 — — US disclosed
US-11142523-B2 1,3-thiazol-2-yl substituted benzamides BAYER AKTIENGESELLSCHAFT (DE) 2021-10-12 — — US disclosed
EP-3230281-B1 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES BAYER AG (DE) 2021-05-26 — — EP disclosed
CN-107207507-B 1, 3-thiazol-2-yl substituted benzamides 拜耳公司 2020-11-06 — — CN disclosed
US-20200131169-A1 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES BAYER AKTIENGESELLSCHAFT (DE) 2020-04-30 — — US disclosed
US-20200131169-A1 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES BAYER AKTIENGESELLSCHAFT (DE) 2020-04-30 — — US disclosed
WO-2007006715-A1 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2007-01-18 — — WO disclosed
WO-2006042150-A1 DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2006-04-20 — — WO disclosed
US-5614518-A Morpholine derivatives as dopamine receptor subtype ligands MERCK SHARP & DOHME LTD. (GB) 1997-03-25 — — US disclosed
EP-0730593-A1 MORPHOLINE DERIVATIVES AS DOPAMINE RECEPTOR SUBTYPE LIGANDS MERCK SHARP & DOHME LTD. (GB) 1996-09-11 — — EP disclosed
CN-1107151-A Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders SANKYO CO (JP) 1995-08-23 — — CN disclosed
WO-1995014690-A1 MORPHOLINE DERIVATIVES AS DOPAMINE RECEPTOR SUBTYPE LIGANDS MERCK SHARP & DOHME LIMITED (GB) 1995-06-01 — — WO disclosed
CN-1028527-C Process for preparing coumarin derivatives SANKYO CO (JP) 1995-05-24 — — CN disclosed
EP-0411912-B1 Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders SANKYO CO (JP) 1995-04-19 — — EP disclosed
CN-1049662-A Coumarin derivative, preparation thereof and application thereof in treating cerebrovascular disorder SANKYO CO (JP) 1991-03-06 — — CN disclosed
EP-0411912-A2 Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders Sankyo Company Limited (JP) 1991-02-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230053411-A1 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES NAT1, HNMT, PMP22 SLC6A2 1015/4885SLC6A4 1244/4885SLC6A3 916/4885
US-11142523-B2 1,3-thiazol-2-yl substituted benzamides NAT1, HNMT, PMP22 SLC6A2 1015/4885SLC6A4 1244/4885SLC6A3 916/4885
US-20200131169-A1 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES NAT1, HNMT, PMP22 SLC6A2 1015/4885SLC6A4 1244/4885SLC6A3 916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.